Company
Esperion Therapeutics
- Status
- IPOas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Developer of HDL therapies to prevent, treat, and reverse cardiovascular and metabolic diseases (NASDAQ:ESPR)
About the company
- Status notes
- (NASDAQ:ESPR)
Loading relationship preview